Arrowstreet Capital Limited Partnership decreased its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 80.4% in the 4th quarter, Holdings Channel reports. The firm owned 114,132 shares of the medical research company’s stock after selling 467,910 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Edwards Lifesciences were worth $12,864,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in EW. APG Asset Management N.V. boosted its holdings in Edwards Lifesciences by 21.4% during the third quarter. APG Asset Management N.V. now owns 66,444 shares of the medical research company’s stock worth $7,263,000 after purchasing an additional 11,700 shares during the last quarter. First Trust Advisors LP acquired a new position in Edwards Lifesciences during the third quarter worth $22,742,000. Aperio Group LLC boosted its holdings in Edwards Lifesciences by 5.7% during the third quarter. Aperio Group LLC now owns 82,174 shares of the medical research company’s stock worth $8,982,000 after purchasing an additional 4,456 shares during the last quarter. First Quadrant L P CA lifted its stake in Edwards Lifesciences by 30.6% in the third quarter. First Quadrant L P CA now owns 83,256 shares of the medical research company’s stock valued at $9,101,000 after acquiring an additional 19,528 shares during the last quarter. Finally, Rehmann Capital Advisory Group lifted its stake in Edwards Lifesciences by 34.9% in the third quarter. Rehmann Capital Advisory Group now owns 2,999 shares of the medical research company’s stock valued at $328,000 after acquiring an additional 776 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.
In related news, VP Donald E. Bobo, Jr. sold 3,750 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $127.54, for a total transaction of $478,275.00. Following the transaction, the vice president now directly owns 19,608 shares of the company’s stock, valued at $2,500,804.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $114.82, for a total transaction of $3,766,096.00. The disclosure for this sale can be found here. Insiders sold 184,230 shares of company stock worth $22,208,032 over the last three months. Insiders own 2.13% of the company’s stock.
Edwards Lifesciences Corp (EW) opened at $136.72 on Tuesday. The firm has a market cap of $28,930.00, a PE ratio of 50.64, a PEG ratio of 2.00 and a beta of 0.63. Edwards Lifesciences Corp has a 1 year low of $89.20 and a 1 year high of $138.48. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The company had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The company’s revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 earnings per share. sell-side analysts predict that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.
Edwards Lifesciences declared that its board has approved a share repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.